BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) granted stock options and restricted stock units to eight newly-hired employees. The options and RSUs total 48,700 and 34,000 shares, respectively, with an exercise price of $5.99 per share. Vesting occurs in four equal annual installments, subject to continued service, with each option having a 10-year term.
01/03/2024 - 04:01 PM
RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired employees stock options to purchase an aggregate of 48,700 shares, and restricted stock units (RSUs) covering an aggregate of 34,000 shares, of BioCryst common stock. The options and RSUs were granted as of December 29, 2023, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $5.99 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.
About BioCryst Pharmaceuticals ® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn .
BCRXW
Contact: jbluth@biocryst.com
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) granted a total of 48,700 shares of stock options to eight newly-hired employees.
The exercise price of the stock options granted by BioCryst Pharmaceuticals, Inc. is $5.99 per share.
The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, subject to the new employee’s continued service with the company.
The ticker symbol of BioCryst Pharmaceuticals, Inc. is BCRX.
Biocryst Pharmaceuticals Inc.
BCRX Rankings
#4914 Ranked by Stock Gains
BCRX Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Durham
About BCRX
biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.
